Article
Cell Biology
Nahla M. Badr, David Spooner, Jane Steven, Andrea Stevens, Abeer M. Shaaban
Summary: This study investigated the effect of NAET on tumour type, grade, and molecular profile in breast cancer patients. Significant changes were observed, including complete pathological response in some cases, central scarring in almost half of the tumours post-treatment, and downgrading of tumour grade in one-third of cases. The study suggests a histological method for assessing residual carcinoma after NAET and recommends repeat ER/PR/HER2 testing for management and prognosis.
Review
Oncology
Jing Xu, Bo Cao, Chunyu Li, Guohui Li
Summary: Breast cancer is a global health concern. Endocrine therapy is crucial in treating estrogen-positive breast cancer, but it often leads to osteoporosis-related adverse events. These events increase the risk of fractures and reduce the patients' quality of life. This review explores the possibility of endocrine therapy-induced osteoporosis in estrogen-positive breast cancer treatment and discusses the mechanisms involved and the potential of drug therapies and combinations.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Juan Chen, Xiaohui Zhang, Yan Lu, Ting Zhang, Zhaolian Ouyang, Qiang Sun
Summary: Extending endocrine therapy from 5 to 7-8 years may improve disease-free survival for postmenopausal patients with HR-positive breast cancer, especially in certain subgroups, but no significant improvement was seen when extending from 7-8 to 10 years. Extended endocrine therapy may be associated with an increased risk of bone fracture and osteopenia/osteoporosis.
Review
Biochemistry & Molecular Biology
Fulvio Borella, Stefano Fucina, Luca Mangherini, Stefano Cosma, Andrea Roberto Carosso, Jessica Cusato, Paola Cassoni, Luca Bertero, Dionyssios Katsaros, Chiara Benedetto
Summary: Epithelial ovarian cancer (EOC) is a leading cause of cancer-related death in women, and its treatment remains challenging with poor survival rates. While the role of hormone receptors (HRs) in EOC has been actively explored, the use of hormone therapy (HT) in treating these tumors is still not well-established. Available data mostly come from retrospective series and small early clinical trials, suggesting that HT may be beneficial in adjuvant therapy, maintenance therapy, or in cases of recurrent disease, particularly for certain subtypes of EOC.
Article
Oncology
Takuji Iwase, Shigehira Saji, Kotaro Iijima, Kenji Higaki, Shoichiro Ohtani, Yasuyuki Sato, Yasuo Hozumi, Yoshie Hasegawa, Yasuhiro Yanagita, Hiroyuki Takei, Maki Tanaka, Hideji Masuoka, Masahiko Tanabe, Chiyomi Egawa, Yoshifumi Komoike, Toshitaka Nakamura, Hiroshi Ohtsu, Hirofumi Mukai
Summary: This study investigated the effects of extending the treatment with an aromatase inhibitor for 10 years on disease-free survival in postmenopausal hormone receptor-positive breast cancer patients. The results showed that extending the treatment with an aromatase inhibitor for an additional 5 years improved disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Sungchan Gwark, Sei Hyun Ahn, Woo Chul Noh, Eun Sook Lee, Yongsik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyungyub Gong, Seon-Ok Kim, Hee Jeong Kim
Summary: The study evaluated patient-reported outcomes (PROs) in a prospective phase III clinical trial comparing neoadjuvant endocrine therapy (NET) with conventional neoadjuvant chemotherapy (NCT) in hormone status positive, lymph node-positive premenopausal breast cancer patients. Overall PROs were similar in both treatment groups, except for future perspective, which was significantly better in the NET group than in the NCT group.
FRONTIERS IN ONCOLOGY
(2021)
Review
Endocrinology & Metabolism
Ailin Zhang, Xiaojing Wang, Chuifeng Fan, Xiaoyun Mao
Summary: Ki67, a proliferation marker, is proposed for breast cancer subtype classification, prognosis, and therapeutic response prediction. However, its questionable analytical validity hinders its widespread adoption in treatment decisions for breast cancer. Studies have shown potential for Ki67 as a predictive marker in neoadjuvant endocrine therapy.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Eileen Rillamas-Sun, Marilyn L. Kwan, Carlos Iribarren, Richard Cheng, Romain Neugebauer, Jamal S. Rana, Mai Nguyen-Huynh, Zaixing Shi, Cecile A. Laurent, Valerie S. Lee, Janise M. Roh, Yuhan Huang, Hanjie Shen, Dawn L. Hershman, Lawrence H. Kushi, Heather Greenlee
Summary: This study investigated the effects of endocrine therapy on cardiovascular disease risk factors in hormone receptor-positive breast cancer survivors. The results suggest that survivors treated with AIs may have a higher risk of developing diabetes, dyslipidemia, and hypertension compared to those not using endocrine therapy.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Leonardo Roberto da Silva, Camila Annicchino de Andrade, Fabricio Brenelli, Susana Ramalho, Tomas Reinert, Alessandra Borba Anton de Souza, Ana Elisa Ribeiro da Silva, Maria Beatriz de Paula Leite Kraft, Vivian Castro Antunes de Vasconcelos, Antonio Luiz Frasson, Renato Zochio Torresan, Cesar Cabello, Matthew J. Ellis, Luiz Carlos Zeferino
Summary: This study reported real-world data of postmenopausal patients receiving neoadjuvant endocrine therapy (NET) for ER-positive/HER2-negative breast cancer. The results showed that NET is effective and safe in this patient population, with postmenopausal status and low-risk luminal tumor features recommended as selection criteria for optimal outcomes.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Sungchan Gwark, Woo Chul Noh, Sei Hyun Ahn, Eun Sook Lee, Yongsik Jung, Lee Su Kim, Wonshik Han, Seok Jin Nam, Gyungyub Gong, Seon-Ok Kim, Hee Jeong Kim
Summary: This study evaluated ALND rates and prognosis in ER+/HER2-, LN-positive, premenopausal breast cancer patients after NCT and NET treatment. The NCT group had a lower ALND rate, higher axillary pCR rate, but there was no significant difference in survival rates compared to the NET group.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Yuji Hayashi, Hiroyuki Takei, Tsuyoshi Saito, Toshihiro Kai, Kenichi Inoue, Masafumi Kurosumi, Jun Ninomiya
Summary: Neoadjuvant exemestane therapy has shown to be effective for older women with hormone sensitive breast cancer. The optimal duration of neoadjuvant exemestane therapy ranges from 22 to 35 months for patients seeking to avoid surgery, and 10 months for patients wishing to receive breast-conserving surgery.
JOURNAL OF NIPPON MEDICAL SCHOOL
(2021)
Article
Oncology
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Summary: This study investigated the effect of adding everolimus to adjuvant therapy in early breast cancer and found that among high-risk patients, adding everolimus to adjuvant endocrine therapy did not improve disease-free survival. Tolerability was also a concern, with more than half of the patients discontinuing everolimus treatment before the study completion.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Raffaella D'Onofrio, Claudia Omarini, Angela Toss, Isabella Sperduti, Federico Piacentini, Monica Barbolini, Laura Cortesi, Elena Barbieri, Elisa Pettorelli, Chiara Chiavelli, Massimo Dominici, Luca Moscetti
Summary: In premenopausal HR + EBC patients, those who received AI/OFS treatment had lower recurrence rate and higher disease-free survival compared to those who received T/OFS treatment. Patients who completed 5-year hormone therapy had significantly higher disease-free survival than those who stopped before 5 years. However, there were adverse events and early discontinuation issues during treatment.
CLINICAL BREAST CANCER
(2023)
Article
Oncology
Ming Xie, Yan Zhong, Yide Yang, Fang Shen, Yue Nie
Summary: The study revealed that extended adjuvant endocrine therapy can improve disease-free survival, overall survival, relapse-free survival, distant metastatic-free survival, reduce the incidence of new breast cancer, but also increase the risk of bone fracture and osteoporosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Luca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, Salvatore Pisconti, Sabrina Rossetti, Zuzana Sirotova, Andrea Muto, Roberto Petrioli, Michele De Tursi, Andrea Sbrana, Giulio Francolini, Antonio Ardizzoia, Claudio Scavelli, Francesco Satta, Silvia Quadrini, Mario Airoldi, Carmine D'Aniello, Andrea Bonetti, Serafino Conforti, Michele Aieta, Patrizia Beccaglia, Antonio Maestri, Lucia Fratino
Summary: This study provides valuable information on the overall management of mCRPC and the effectiveness of first-line abiraterone and docetaxel in a population representative of everyday practice.
Article
Biotechnology & Applied Microbiology
Pietro Di Marino, Cosima Chiapperino, Francesca Chiara Primavera, Maria Teresa Martino, Davide Brocco, Consiglia Carella, Antonino Grassadonia, Nicola Tinari, Michele De Tursi
Summary: This case report describes a patient with EGFR-mutated NSCLC who developed pancytopenia during treatment with osimertinib, but showed excellent activity after dose reduction. This suggests that osimertinib can be safely resumed at a reduced dose even after adverse events.
ONCOTARGETS AND THERAPY
(2022)
Article
Chemistry, Multidisciplinary
Francesco Agostini, Massimiliano Mangone, Nikolaos Finamore, Marta Di Nicola, Federico Papa, Giuliano Alessio, Luigi Vetrugno, Angelo Chiaramonte, Giorgia Cimbri, Andrea Bernetti, Marco Paoloni, Teresa Paolucci
Summary: In comparing ESWT to placebo, ESWT was found to be effective. However, more randomized trials are needed to compare different types and intensities of shockwave therapy in order to obtain more precise information on its effectiveness.
APPLIED SCIENCES-BASEL
(2022)
Article
Medicine, General & Internal
Paola Monari, Giulio Gualdi, Giorgio Bettoni, Raffaella Costa, Giorgio Ragni, Francesca Zani, Giovanna Bianchi, Silvia Casella, Elisa Casella, Massimo Crippa, Piergiacomo Calzavara Pinton, Marta Di Nicola, Annamaria Porreca, Paolo Amerio, Pierangelo Guizzi
Summary: Post-infection acute telogen effluvium occurs in a significant number of COVID-19 patients and may have a significant impact on their quality of life.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Davide Brocco, Pasquale Simeone, Davide Buca, Pietro Di Marino, Michele De Tursi, Antonino Grassadonia, Laura De Lellis, Maria Teresa Martino, Serena Veschi, Manuela Iezzi, Simone De Fabritiis, Marco Marchisio, Sebastiano Miscia, Alessandro Cama, Paola Lanuti, Nicola Tinari
Summary: This study examined the prognostic and predictive value of blood circulating EVs in patients with mCRC. Increased concentrations of tumor-induced blood circulating EVs, specifically CD133+ EVs, were associated with poor clinical outcomes. These findings suggest that EVs may serve as potential biomarkers for risk stratification and treatment selection in mCRC.
Review
Oncology
Antonino Grassadonia, Antonella De Luca, Erminia Carletti, Patrizia Vici, Francesca Sofia Di Lisa, Lorena Filomeno, Giuseppe Cicero, Laura De Lellis, Serena Veschi, Rosalba Florio, Davide Brocco, Saverio Alberti, Alessandro Cama, Nicola Tinari
Summary: Gastric cancer is a major global cause of tumor-related death. Adjuvant systemic chemotherapy after surgery has been proven to improve outcomes, but approaches vary worldwide. Identifying high-risk patients and personalizing treatment are important considerations.
Article
Oncology
Eriseld Krasniqi, Francesca Sofia Di Lisa, Anna Di Benedetto, Maddalena Barba, Laura Pizzuti, Lorena Filomeno, Cristiana Ercolani, Nicola Tinari, Antonino Grassadonia, Daniele Santini, Mauro Minelli, Filippo Montemurro, Maria Agnese Fabbri, Marco Mazzotta, Teresa Gamucci, Giuliana D'Auria, Claudio Botti, Fabio Pelle, Flavia Cavicchi, Sonia Cappelli, Federico Cappuzzo, Giuseppe Sanguineti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Marcello Maugeri-Sacca, Ruggero De Maria, Gennaro Ciliberto, Francesca Sperati, Patrizia Vici
Summary: This study investigated the impact of immunohistochemical expression of Hippo pathway transducers and cell metabolism regulators on the outcome of neoadjuvant treatment in Her2+ breast cancer patients. The results showed that low expression of TAZ, especially when combined with low expression of YAP and HMGCR and high expression of SCD1, may be a negative predictor of treatment response. However, further studies with a larger sample size are needed to validate these findings.
Article
Oncology
Davide Brocco, Domenico De Bellis, Pietro Di Marino, Pasquale Simeone, Antonino Grassadonia, Michele De Tursi, Tommaso Grottola, Fabio Francesco Di Mola, Patrizia Di Gregorio, Barbara Zappacosta, Antonio Angelone, Laura De Lellis, Serena Veschi, Rosalba Florio, Simone De Fabritiis, Fabio Verginelli, Marco Marchisio, Marta Caporale, Dimitri Luisi, Pierluigi Di Sebastiano, Nicola Tinari, Alessandro Cama, Paola Lanuti
Summary: This study explores the potential of blood-circulating extracellular vesicles released by immune cells as biomarkers in patients with pancreatic cancer. The results show that patients with pancreatic cancer have higher levels of LEVs and PD-L1+ EVs in their blood compared to healthy controls, and a high concentration of LEVs is associated with improved prognosis and clinical outcomes.
Article
Microbiology
Claudio Ucciferri, Alessandro Di Gasbarro, Paola Borrelli, Marta Di Nicola, Jacopo Vecchiet, Katia Falasca
Summary: This study found that the use of pidotimod in patients with mild-moderate COVID-19 can reduce the need for hospitalization and shorten the duration of illness. Patients in the pidotimod group had higher SpO2 in the walking test and a lower need for steroid rescue therapy.
Article
Microbiology
Michela Pontolillo, Claudio Ucciferri, Paola Borrelli, Marta Di Nicola, Jacopo Vecchiet, Katia Falasca
Summary: This study reports the experience of using molnupiravir in the treatment of COVID-19 patients. The results show that participants demonstrated early clinical improvement, no need for hospitalization, and a low rate of adverse events after receiving the treatment.
Article
Environmental Sciences
Erica Costantini, Marta Di Nicola, Michele Marchioni, Lisa Aielli, Marcella Reale, Luigi Ships
Summary: This study evaluated the effects of curcumin and lactoferrin on prostate cancer cells and found that their effects were different between different cell lines. The combination of the two substances was effective in reducing the aggressiveness of cancer cells.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Medicine, General & Internal
Lisa Toto, Maria Ludovica Ruggeri, Federica Evangelista, Chiara Trivigno, Rossella D'Aloisio, Chiara De Nicola, Pasquale Viggiano, Emanuele Doronzo, Marta Di Nicola, Annamaria Porreca, Rodolfo Mastropasqua
Summary: This study investigates the parameters of optical coherence tomography (OCT) and OCT angiography (OCTA) in patients with neovascular age-related macular degeneration (nAMD) and macular neovascularization (MNV) types 1, 2, and 3. The results showed significant differences in CVI, CMT, and ORCCFA between MNV 1 and the other two groups. CVI was significantly different between MNV 1 and healthy controls and between MNV 1 and MNV 2. ORCCFA and CMT were significantly different between MNV 1 and MNV 2. There was no statistically significant difference in subfoveal choroidal thickness (SFCT) among the three groups.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Stefano Granieri, Christian Cotsoglou, Alessandro Bonomi, Lisa Salvatore, Roberto Filippi, Olga Nigro, Fabio Gelsomino, Ina Valeria Zurlo, Ilaria Depetris, Riccardo Giampieri, Rossana Berardi, Cristina Morelli, Michele De Tursi, Michela Roberto, Elson Gjoni, Alessandro Germini, Nicola de Angelis, Riccardo Memeo, Antonio Facciorusso, Ornella Garrone, Daryl Ramai, Michele Ghidini, Alessandro Parisi
Summary: In patients with left-sided RAS/BRAF wild-type colorectal cancer and liver-limited metastatic disease, a conversion strategy can improve survival outcomes. There is no difference in survival between ultimately resectable patients and those who had liver resection with perioperative systemic treatment.
Article
Biochemistry & Molecular Biology
Michele Sallese, Konstantinos Efthymakis, Michele Marchioni, Benedetto Neri, Beatrice Dufrusine, Enrico Dainese, Marta Di Nicola, Matteo Neri
Summary: Coeliac disease (CeD) is an immune-mediated disorder triggered by gluten, involving autoimmune damage to the intestines and other systems. The Th1 inflammatory response and innate immune response play important roles in its pathogenesis. Gene expression analysis found key cytokines and immune pathways involved. Comparison with non-celiac gluten sensitivity (NCGS) revealed molecular overlap, suggesting a common root (dysregulated long non-coding RNAs) for these diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.